The Senate Health and Welfare Committee debated a bill that would require Medicaid to cover FDA-approved weight-loss ...

Incretin-based obesity medications may result in higher muscle-related loss vs. other weight loss strategies, according to ...

Childhood obesity is linked to lower chances of earning more than one’s parents in adulthood. Researchers used long-term data ...

High doses of the dual agonist tirzepatide appear to provide greater weight loss than other GLP-1s among adults with ...

Plus, expert-backed tips for protecting your bones.

April 16 () - Eli Lilly said on Thursday its newly approved obesity ‌pill helped reduce the risk ‌of major cardiovascular ...

In new research being presented at the European Congress on Obesity in Istanbul, Turkey (12–15 May) and published in The ...

Tirzepatide is associated with a greater mean percent body weight reduction than semaglutide in adults with obesity or overweight and one or more related complications.

The ACHIEVE-4 trial evaluated the efficacy and safety of orforglipron in adults with type 2 diabetes and obesity or overweight with increased risk of cardiovascular events.

Note – this is an early press release from the European Congress on Obesity in Istanbul, Turkey, 12-15 May. Please credit the congress when using this research* In new research to be presented at this ...